Analyst Ratings for Intra-Cellular Therapies (ITCI)
ITCI Rating Summary
ITCI Price Target Summary
- Highest: $101.00 (Cantor Fitzgerald)
- Lowest: $62.00 (JPMorgan)
- Average: $81.46
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$81.46 (+24.6%)
* Over Last 12-Mos
Rating Score: 8.5 / 10 Percentile Rank: 87%
Rating Score: 8.5 / 10 Percentile Rank: 87%
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
1/3/2024 | Baird | Joel Beatty | New Coverage | Outperform (N/A) |
83.00 (N/A) |
71.62 (65.37) |
-8.73% | Details |
12/11/2023 | TD Cowen | Joseph Thome | New Coverage | Outperform (N/A) |
75.00 (N/A) |
60.29 (65.37) |
8.43% | Details |